Gabelli Funds LLC Verve Therapeutics, Inc. Transaction History
Gabelli Funds LLC
- $12.9 Billion
- Q2 2025
A detailed history of Gabelli Funds LLC transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Gabelli Funds LLC holds 267,520 shares of VERV stock, worth $2.98 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
267,520Holding current value
$2.98 Million% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding VERV
# of Institutions
178Shares Held
71.2MCall Options Held
452KPut Options Held
2.96M-
Alphabet Inc. Mountain View, CA12.2MShares$135 Million8.86% of portfolio
-
Pentwater Capital Management LP Naples, FL6.72MShares$74.8 Million0.5% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$73.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.19MShares$46.7 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY4.1MShares$45.6 Million6.45% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $667M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...